The p53 tumor suppressor gene is mutated in approximately half of all human malignancies, including colon, lung, and breast cancers. It is well recognized that these mutations directly inactivate p53 tumor suppressor function. Furthermore, the p53 protein operates within a pathway and this pathway,...
This is a heavily studied pathway in cancer biology and oncology with a history that dates back to 1979 when p53 was discovered. The p53 pathway is a complex cellular stress response network with multiple diverse inputs and downstream outputs relevant to its role as a tumor suppressor pathway....
[8].Joerger A C, Fersht A R. Structural biology of the tumor suppressor p53[J]. Annu. Rev. Biochem., 2008, 77: 557-582. [9].Joerger A C, Fersht A R. The p53 pathway: origins, inactivation in cancer, and emerging therapeutic approaches[J]. Annual review of biochemistry, 2016, 8...
L. Disruption of the ARF–Mdm2–p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 13, 2658–2669 (1999). CAS PubMed PubMed Central Google Scholar Schmitt, C. A., McCurrach, M. E., de Stanchina, E., Wallace-Brodeur, R. R. & Lowe, S. W. INK4a/ARF ...
【2】Kussie, Paul H., et al. "Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain." Science 274.5289 (1996):948-953.doi:10.1126/science.274.5289.948 【3】Tyler, Andrew F. , et al. "Reactivation of the p53 tumor suppressor pathway by a stapled ...
Molecular biology Mechanistic studies of the ARF-p53 tumor suppressor pathway COLUMBIA UNIVERSITY Wei Gu AbidaWassim MThe p53 tumor suppressor has been dubbed the "guardian of the genome" because of its central role in the cellular response to stress. p53 functions as a transcription factor that ...
[7].Lacroix M, Riscal R, Arena G, Linares LK, Le Cam L. Metabolic functions of the tumor suppressor p53: Implications in normal physiology, metabolic disorders, and cancer. Mol Metab. 2020;33:2-22. doi:10.1016/j....
[6]Na Kong et al. Synthetic mRNA nanoparticle-mediated restoration of p53 tumor suppressor sensitizes p53-deficient cancers to mTOR inhibition. Science Translational Medicine(2019).
5. Kussie PH, Gorina S, Marechal V, et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.Science.1996;274(5289):948-953. doi:10.1126/science.274.5289.948 6. Chène P, Fuchs J, Bohn J, García-Echeverría C, Furet P, Fabbro D. A small sy...
当罗氏的科学家Lyubomir Vassilev在2003年开始写有关他的团队发现了抑制p53–MDM2相互作用的小分子抑制剂的文章时,他已经预测到,这篇论文会引发热议。因为,p53是人类癌症中突变最频繁的基因,而他的团队已经发现了能够选择性增强该肿瘤抑制因子活性的化合物。为了纪念这